Bendamustine hydrochloride is a bifunctional chemotherapeutic agent with structurally similar to alkylating agents and purine analogues.

Bendamustine  hydrochloride is a bifunctional chemotherapeutic agent with structurally similar to alkylating agents and purine analogues. However, it has a distinct mechanism of action. This agent, alone or in combination with other chemotherapeutic agents, has been shown to produce good clinical efficacy and acceptable tolerability in patients with Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin’s Lymphoma (NHL) and Multiple myeloma (MM).

 

Indications:

  •  For the treatment of Symptomatic Chronic Lymphocytic Leukemia (CLL) patients who have received no prior treatment.
  • Relapsed indolent B-cell Non-Hodgkin Lymphoma (iNHL) patients who did not respond to or progressed during or shortly following treatment with a rituximab regimen.
  • Front line treatment of Multiple myeloma (MM) patients in combination with prednisone who are not eligible for autologous stem cell transplantation.

 

GenericName

Strength

Standard

Type

Packing

Pack Size

Bendamustine

100 mg

IP

INJ

Vial

 1 Vial